AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 784 businesses audited.
Medical Devices, Pharma & Biotech BS: Repatha (Amgen) (repatha.com)
Repatha offers a substantive medical product packaged in an overly engineered ‘human-centric’ marketing shell. While the clinical data is robust and likely scientifically accurate, the site’s reliance on unverified patient stories and a total lack of structured data schema creates a measurable distance between its regulatory signal and its digital substance.
Replace the vague [H1] ‘Repatha® can help’ with a substance-led heading like ‘Repatha®: 63% Average LDL-C Reduction in 3 Months.’ Implement comprehensive Product and MedicalWebPage schema to bridge the technical authority gap. Add direct outbound citations to the peer-reviewed publications for the FOURIER or cardiovascular outcomes trials mentioned. Replace the robotic Sam metaphor with a technical ‘Mechanism of Action’ section to increase expert-level information density.
The information density is a tale of two extremes. Headings like [H1] ‘Repatha® can help’ and [H3] ‘BECAUSE YOU’RE HUMAN’ are pure emotional fluff with 0% substance. However, the body text is packed with highly specific clinical evidence, such as the ‘63% average reduction’ in LDL-C and the ‘27%’ reduction in heart attack risk. The score is penalised for high concept repetition regarding the Co-Pay card across all four pages.
AI does not see your layout — it sees your DOM. Get a Clinical Semantic Structure Diagnosis to reveal how your page is segmented, weighted, and interpreted.
There is minor semantic drift between the homepage’s high-level ’emotional support’ signals and the sub-page’s granular ‘clinical trial’ data. While the homepage focuses on the user’s journey and ‘letting us tell you more about you,’ the ‘What is Repatha’ page shifts into hard medical statistics. The alignment is generally strong, but the transition from patient-lifestyle marketing to technical pharma data is abrupt.
Our Authority as a Service model transforms raw diagnostic data into high stakes results. Start your Clinical Strategic Diagnosis for 1 Euro to secure the strategic fixes required for growth.
The site exhibits high Trust Theatre. While it features ‘real Repatha patients’ like Cathy and Jerry, these testimonials are presented with a review_count of 2-4 but a proof_links_count of 0, meaning the ‘success stories’ lack external verification paths or linked case study documentation. The trust_theatre_flag is true across all pages because of these unsubstantiated patient efficacy claims.
Proof density is high regarding internal metrics but low regarding external validation. The site provides at least 6 specific clinical data points (63%, 84%, 27%, 21%, 55%, 36%), which is excellent substance, but provides 0 external proof links in the structured data. This creates a closed-loop authority structure where the user must trust Amgen’s self-reported summaries.
To evaluate URL identity stability and multilingual coherence, review the Yoast Identity Stability audit. View the Yoast Identity Stability Audit for a practical example of canonical alignment and language layer integrity.
The site relies heavily on industry cliches and value prop cliches like ‘breakthrough medicine’ and ‘Where science meets compassion’ (implied by the robot Sam metaphor). The Sam the Robot narrative is a textbook pharma template for ‘humanising’ a drug. Furthermore, the ‘Important Safety Information’ and ‘Approved Use’ blocks are necessary but follow a standardized boilerplate fingerprint found across the entire pharmaceutical sector.
There is a significant technical authority gap; despite being a major global drug, the schema_json is null across all pages, missing critical Organization or Product structured data. While ‘Cathy’ and ‘Jerry’ are cited as authorities of experience, they have no digital footprint or Person schema. The site lacks outbound links to the specific peer-reviewed studies mentioned, relying instead on internal text assertions.
The marketing tone uses bold assertions like ‘dramatically lower bad cholesterol,’ but unlike generic BS sites, Repatha actually backs this with specific numbers (84% of patients below 55 mg/dL). The disconnect is not in the truth of the claims, but in the lack of direct citations to ClinicalTrials.gov or published journals within the body text to verify the ’10 Years of Impact’ claim.
Medical Devices, Pharma & Biotech BS: Repatha (Amgen) (repatha.com)
The site perfectly matches the Pharma & Biotech industry, evidenced by extensive ‘Important Safety Information’ blocks, ‘Approved Use’ declarations, and specific clinical data metrics for evolocumab. It follows high-compliance regulatory patterns typical of FDA-regulated prescription medication pages.
If your structural signals drift, the model cannot form stable chunks or coherent embeddings. Study the Semantic HTML Framework Guide and see why semantic structure — not styling — controls AI comprehension.
“The score of 39 is driven primarily by the Commodity Fingerprint (11) and Trust Theatre (8) pillars. While the site is medically substantive, its marketing delivery is highly derivative of standard pharma templates and it fails to provide verifiable links for its patient reviews or implement modern technical authority signals (Schema).”
Analysis Disclosure & Source Attribution
Snapshot Date: June 19, 2026
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to see how machine logic interprets digital signals.
Machine Perception Notice: This evaluation is generated by machine-read logic (MRL). The AI interprets the “Digital Ghost” of a website (code, metadata, and semantic structures), which may differ from what a human sees at the same moment. This is an automated technical diagnostic and not a statement of fact or human opinion regarding the real-world integrity or legitimacy of the business. Any missing or inaccessible elements in the snapshot are treated as machine-read signals, reflecting AI rendering limitations rather than intentional omission.
Notice to the Evaluated Business: This analysis is part of a non-adversarial audit. The results are intended as professional feedback to help improve machine-readability and authority signals. Any company can use these insights for free. When content is updated, a fresh audit can be requested at any time to reflect the current state.
To All Users: You are encouraged to visit the live site at Repatha (Amgen) to view the most current version of their content and see directly what the company offers.